CAS: 1308672-74-3; N-(2-(Dimethylamino)Ethyl)-1-(3-((4-((2-Methyl-1H-Indol-5-yl)Oxy)Pyrimidin-2-yl)Amino)Phenyl)Methanesulfonamide
- 英文名称N-(2-(Dimethylamino)Ethyl)-1-(3-((4-((2-Methyl-1H-Indol-5-yl)Oxy)Pyrimidin-2-yl)Amino)Phenyl)Methanesulfonamide
- 中文名称N-(2-(二甲基氨基)乙基)-1-(3-((4-((2-甲基-1H-吲哚-5-基)氧基)嘧啶-2-基)氨基)苯基)甲烷磺酰胺
- IUPAC名称N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1H-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
- CAS编号1308672-74-3
- MFCD编号:MFCD28359080
- FDA UNII编号:B2K5L1L8S9
- 分子式:C24H28N6O3S分子量:480.59
- 产品CID: 468068
- 同类组份化合物CAS1308672-74-31816307-67-1.
- 产品分类原料药
物理性质
上下游产品
5-((2-Chloropyrimidin-4-yl)Oxy)-2-Methyl-1H-Indole 1071105-16-2合成工艺路线路线简述
- 合成目标产物 N-(2-(Dimethylamino)Ethyl)-1-(3-((4-((2-Methyl-1H-Indol-5-yl)Oxy)Pyrimidin-2-yl)Amino)Phenyl)Methanesulfonamide 主要起始原料 5-((2-Chloropyrimidin-4-yl)Oxy)-2-Methyl-1H-Indole And 1-(3-Aminophenyl)-N-(2-(Dimethylamino)Ethyl)Methanesulfonamide
- (文献来源)合成步骤主要原料 5-((2-Chloropyrimidin-4-yl)Oxy)-2-Methyl-1H-Indole 和 1-(3-Aminophenyl)-N-(2-(Dimethylamino)Ethyl)Methanesulfonamide
📜5-((2-Chloropyrimidin-4-yl)Oxy)-2-Methyl-1H-Indole,1-(3-氨基苯基)-N-(2-(二甲氨基)乙基)甲烷磺酰胺置于1-(3-氨基苯基)-N-(2-(二甲氨基)乙基)甲烷磺酰胺体系中,化学反应生成N-(2-(二甲基氨基)乙基)-1-(3-((4-((2-甲基-1H-吲哚-5-基)氧基)嘧啶-2-基)氨基)苯基)甲烷磺酰胺
参考文献:Compound,Certain Novel Forms Thereof,Pharmaceutical Compositions Thereof And Methods For Preparation And Use
标题:Compound,Certain Novel Forms Thereof,Pharmaceutical Compositions Thereof And Methods For Preparation And Use
摘要:化合物a及其药学上可接受的盐和化合物a的结晶形式i和ii的复合物!此外,还提供制备这些化合物的方法,包括这些化合物的制药组合物和使用这些化合物的方法.
海关参考信息
- 2902300000-甲苯
2921211000-乙二胺
2908199090-其他酚的卤化衍生物
2908999090-其他酚的硝化衍生物 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12390420-B1
优先权日:2024-10-22
标题 :Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof
发明人：EGUCHI MASAKATSU
权利人:BRYET US INC
摘要:The present disclosure provides compositions and methods for delivering therapeutic agents to particular tissues or cells in a subject. The composition disclosed herein combines unique properties of porous micro- or nano-particles with host-guest chemistry provided by functionalized silicon particle, offering a versatile approach to addressing the challenges associated with delivering therapeutic agents to target tissues or sites within the body. The present disclosure also provides a method for synthesizing a composition capable of delivering therapeutic agents to particular tissues or cells in a subject.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Lin Q, Dai S, Qu L, Lin H, Guo M, Wei H, Chen Y, Chen X. Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R. Commun Chem. 2024 Jan 3;7(1):3. doi: 10.1038/s42004-023-01084-0.
2: Liao S, Li J, Gao S, Han Y, Han X, Wu Y, Bi J, Xu M, Bi W. Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1-3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment. Front Oncol. 2023 Jun 8;13:1158857. doi: 10.3389/fonc.2023.1158857.
3: Cai T, Cheng Y, Du Y, Tan P, Li T, Chen Y, Gao L, Fu W. Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis. Oncol Lett. 2023 May 10;25(6):273. doi: 10.3892/ol.2023.13859.
合成参考文献
参考文献:10.1007/s00432-021-03898-8
摘要:Cao Y, Lu M, Sun Y, Gong J, Li J, Lu Z, Li J, Zhang X, Li Y, Peng Z, Zhou J, Wang X, Shen L. Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial. Journal of Cancer Research and Clinical Oncology. 2022 Feb 15;():1–11. doi: 10.1007/s00432-021-03898-8.
📝 需求与反馈
尽可能描述清楚需求与问题信息
